Telormedix SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Telormedix SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013217
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Telormedix SA (Telormedix) is a biopharmaceutical company. The company develops and provides immune drugs for the treatment of cancer and other infectious diseases. It offers products such as TMX-201, TMX-202 and vesimune (TMX-101). Its vesimune (TMX-101) provides treatment for superficial bladder cancer, skin and other viral diseases; TMX-201 provides vaccine adjuvant. Its TMX-202 product shows indication about different cancer types. Telormedix also has collaborations with University California San Diego that develops small molecules, which can modulate innate immunity. It also has collaborations with various research institutions and industry enterprises. Telormedix is headquartered in Bioggio, Switzerland.

Telormedix SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Telormedix SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Telormedix SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Telormedix SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Telormedix SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Telormedix SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Telormedix SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Telormedix Raises US$6.6 Million In Extended Series B Financing 10
Telormedix Raises US$8 Million In Series B Financing 12
Partnerships 13
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 13
Asset Transactions 14
UroGen Pharma Acquires All Intellectual Property Assets from Telormedix 14
Telormedix SA – Key Competitors 15
Telormedix SA – Key Employees 16
Telormedix SA – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Telormedix SA, Pharmaceuticals & Healthcare, Key Facts 2
Telormedix SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Telormedix SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Telormedix SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Telormedix SA, Deals By Therapy Area, 2011 to YTD 2017 8
Telormedix SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Telormedix Raises US$6.6 Million In Extended Series B Financing 10
Telormedix Raises US$8 Million In Series B Financing 12
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 13
UroGen Pharma Acquires All Intellectual Property Assets from Telormedix 14
Telormedix SA, Key Competitors 15
Telormedix SA, Key Employees 16

★海外企業調査レポート[Telormedix SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bayer Healthcare Pharmaceuticals:企業の戦略・SWOT・財務情報
    Bayer Healthcare Pharmaceuticals - Strategy, SWOT and Corporate Finance Report Summary Bayer Healthcare Pharmaceuticals - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • DNO ASA (DNO):企業の財務・戦略的SWOT分析
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It also provides operations in petroleum, shipp …
  • PCCW Limited:戦略・SWOT・企業財務分析
    PCCW Limited - Strategy, SWOT and Corporate Finance Report Summary PCCW Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Banco Comercial Portugues SA:企業の戦略・SWOT・財務分析
    Banco Comercial Portugues SA - Strategy, SWOT and Corporate Finance Report Summary Banco Comercial Portugues SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • TomTom NV (TOM2):企業の財務・戦略的SWOT分析
    TomTom NV (TOM2) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Applied Genetic Technologies Corp (AGTC):企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. AGTC offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis …
  • Srei Infrastructure Finance Ltd
    Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report Summary Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • OSRAM Licht AG:企業のM&A・事業提携・投資動向
    OSRAM Licht AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's OSRAM Licht AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Tidewater Midstream and Infrastructure Ltd (TWM):石油・ガス:M&Aディール及び事業提携情報
    Summary Tidewater Midstream and Infrastructure Ltd (Tidewater Midstream) is a midstream and infrastructure company. It is involved in purchasing, sale and transportation of NGLs and export to overseas markets. The company engaged in selective acquisitions, organic growth projects, and optimization o …
  • Marico Limited (MARICO):企業の財務・戦略的SWOT分析
    Marico Limited (MARICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Enercon GmbH:企業の戦略的SWOT分析
    Enercon GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Agile Therapeutics Inc (AGRX):企業の財務・戦略的SWOT分析
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …
  • Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析
    Summary Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a medical biotechnology company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company designs and develops immunomodulator microparticle technology. Innat …
  • AnaMar AB:医療機器:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • Lahey Hospital and Medical Center:企業の戦略的SWOT分析
    Lahey Hospital and Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Caladrius Biosciences Inc (CLBS):企業の財務・戦略的SWOT分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company’s lead product CLBS03 is …
  • Toa Corp (1885):企業の財務・戦略的SWOT分析
    Toa Corp (1885) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • University of Texas Health Science Center at Houston-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at Houston (UTHealth), a subsidiary of University of Texas System is an educational institution that provides research, education and patient care services. The university operates with schools of biomedical informatics, biomedical sciences, dentistr …
  • Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor …
  • Helm AG:戦略・SWOT・企業財務分析
    Helm AG - Strategy, SWOT and Corporate Finance Report Summary Helm AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆